

### PATIENT INFORMATION

Patient Name: \_\_\_\_\_ DOB: \_\_\_\_\_ Phone: \_\_\_\_\_ Sex: M F Ht: \_\_\_\_\_ Wt: \_\_\_\_\_ lbs kg  
 Primary Language: \_\_\_\_\_ Allergies: \_\_\_\_\_  
 Patient Preferred Location: \_\_\_\_\_

### DIAGNOSIS & CLINICAL INFORMATION

<ICD 10 CODE REQUIRED>

**ICD 10 Code (PROVIDE COMPLETE CODE)**

- |  |   |
|--|---|
| K50.0 _____ Crohn's Disease, Small Intestine         | K51.8 _____ Other Ulcerative Colitis, Chronic         |
| K50.1 _____ Crohn's Disease, Large Intestine         | K51.5. _____ Left Sided - Ulcerative Colitis, Chronic |
| K50.8 _____ Crohn's Disease, Small & Large Intestine | K51.0. _____ Universal Ulcerative Pancolitis, Chronic |
| K50.9 _____ Crohn's Disease, Unspecified             | K51.9 _____ Ulcerative Colitis, Unspecified           |

Other: \_\_\_\_\_

**REQUIRED:** Demographics & Most Recent: H&P, clinical notes, & medication list. Supporting clinical notes to include any past tried and/or failed therapies, intolerance, outcomes, or contraindications to conventional therapy.

**LAB RESULTS:** Include Negative TB within 12 months.

### PRESCRIPTION

**Pre-Medications**

- Acetaminophen: 650 mg PO
- Cetirizine: 10 mg PO
- Diphenhydramine: 25 mg PO
- Diphenhydramine: 25 mg IVP
- Famotidine: 20 mg PO
- Methylprednisolone: 125 mg SIVP

Other: \_\_\_\_\_

**Lab Orders+**

*Required:* Negative TB, annually

**+Medix Infusion will draw maintenance labs unless otherwise directed by Referring Provider**

**ENTYVIO (vedolizumab)**

**Loading Dose**

**IV:** Infuse 300 mg in 250 mL of 0.9% Sodium Chloride over at least 30 minutes at weeks 0, 2, 6

**Maintenance Dose (SELECT ONE)**

**IV:** Infuse 300 mg in 250 mL of 0.9% Sodium Chloride over at least 30 minutes every 8 weeks for one year

**IV:** Infuse 300 mg in 250 mL of 0.9% Sodium Chloride over at least 30 minutes every \_\_\_\_\_ weeks for one year

Following each infusion, flush with 30 mL 0.9% Sodium Chloride

**Post Treatment Observations:** The patient is observed for 30 minutes following the first administration.

**Adverse Events:** In the event of an adverse reaction occurring at a Medix Infusion suite, utilize the Medix Infusion adverse reactions protocol.

**Comments:**

\_\_\_\_\_  
 \_\_\_\_\_

### PRESCRIBER INFORMATION

Prescriber Name: \_\_\_\_\_ Signature: \_\_\_\_\_

Date: \_\_\_\_\_ NPI #: \_\_\_\_\_ Specialty: \_\_\_\_\_

Supervising Physician: \_\_\_\_\_ (If Applicable)

Address: \_\_\_\_\_ City: \_\_\_\_\_ State: \_\_\_\_\_ Zip: \_\_\_\_\_

Contact Name: \_\_\_\_\_ Phone: \_\_\_\_\_ Fax: \_\_\_\_\_ Email: \_\_\_\_\_